XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-82.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XTLB vs BFRI
Revenue, margins, valuation, and 5-year total return — side by side.
BFRI
Biofrontera Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$13M
5Y Perf.-98.7%
XTLB vs BFRI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XTLB | BFRI |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $294K | $13M |
| Revenue (TTM) | $451K | $42M |
| Net Income (TTM) | $-1M | $-11M |
| Gross Margin | 26.4% | 75.8% |
| Operating Margin | -481.6% | -27.2% |
| Total Debt | $138K | $6M |
| Cash & Equiv. | $371K | $6M |
XTLB vs BFRI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XTLB
BFRI
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| XTL Biopharmaceutic… (XTLB) | 100 | 17.5 | -82.5% |
| Biofrontera Inc. (BFRI) | 100 | 1.3 | -98.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XTLB vs BFRI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BFRI leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
XTLB
XTL Biopharmaceuticals Ltd.
The Long-Run Compounder
XTLB is the clearest fit if your priority is long-term compounding.
- -87.3% 10Y total return vs BFRI's -98.7%
- -17.7% ROA vs BFRI's -52.2%, ROIC -54.1% vs -124.3%
Best for: long-term compounding
BFRI
Biofrontera Inc.
The Income Pick
BFRI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.67
- Rev growth 11.8%, EPS growth 100.0%, 3Y rev CAGR 13.3%
- Lower volatility, beta 1.67, Low D/E 58.8%, current ratio 1.52x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BFRI | 11.8% revenue growth vs XTLB's -173.2% |
| Quality / Margins | BFRI | -25.3% margin vs XTLB's -227.7% |
| Stability / Safety | BFRI | Beta 1.67 vs XTLB's 1.71 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BFRI | +62.5% vs XTLB's -50.9% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs BFRI's -52.2%, ROIC -54.1% vs -124.3% |
XTLB vs BFRI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
XTLB vs BFRI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBFRILAGGINGXTLB
XTLBXTL Biopharmaceutical…
2leads
BFRIBiofrontera Inc.
3leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BFRI5/5
Valuation MetricsMultiples, price ratios, and targets
BFRI1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB4/6
Risk & VolatilityBeta, volatility, and downside exposure
BFRI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BFRI leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
BFRI is the larger business by revenue, generating $42M annually — 92.5x XTLB's $451,000. Profitability is closely matched — net margins range from -25.3% (BFRI) to -2.3% (XTLB).
| Metric | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. |
|---|---|---|
| RevenueTrailing 12 months | $451,000 | $42M |
| EBITDAEarnings before interest/tax | -$1M | -$11M |
| Net IncomeAfter-tax profit | -$1M | -$11M |
| Free Cash FlowCash after capex | $0 | -$13M |
| Gross MarginGross profit ÷ Revenue | +26.4% | +75.8% |
| Operating MarginEBIT ÷ Revenue | -4.8% | -27.2% |
| Net MarginNet income ÷ Revenue | -2.3% | -25.3% |
| FCF MarginFCF ÷ Revenue | -3.7% | -32.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +36.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +20.0% | +100.0% |
BFRI leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
BFRI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. |
|---|---|---|
| Market CapShares × price | $293,767 | $13M |
| Enterprise ValueMkt cap + debt − cash | $60,767 | $13M |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | — |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.65x | 0.32x |
| Price / BookPrice ÷ Book value/share | 0.05x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
BFRI leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
XTLB leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-11 for BFRI. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to BFRI's 0.59x. On the Piotroski fundamental quality scale (0–9), BFRI scores 4/9 vs XTLB's 3/9, reflecting mixed financial health.
| Metric | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -25.5% | -11.4% |
| ROA (TTM)Return on assets | -17.7% | -52.2% |
| ROICReturn on invested capital | -54.1% | -124.3% |
| ROCEReturn on capital employed | -50.7% | -84.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.59x |
| Net DebtTotal debt minus cash | -$233,000 | -$231,000 |
| Cash & Equiv.Liquid assets | $371,000 | $6M |
| Total DebtShort + long-term debt | $138,000 | $6M |
| Interest CoverageEBIT ÷ Interest expense | -13.31x | -69.93x |
XTLB leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $1,963 today (with dividends reinvested), compared to $129 for BFRI. Over the past 12 months, BFRI leads with a +62.5% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors XTLB at -18.4% vs BFRI's -54.4% — a key indicator of consistent wealth creation.
| Metric | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +11.3% | +57.2% |
| 1-Year ReturnPast 12 months | -50.9% | +62.5% |
| 3-Year ReturnCumulative with dividends | -45.7% | -90.5% |
| 5-Year ReturnCumulative with dividends | -80.4% | -98.7% |
| 10-Year ReturnCumulative with dividends | -87.3% | -98.7% |
| CAGR (3Y)Annualised 3-year return | -18.4% | -54.4% |
XTLB leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
BFRI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BFRI is the less volatile stock with a 1.67 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BFRI currently trades 95.8% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 1.67x |
| 52-Week HighHighest price in past year | $10.28 | $1.19 |
| 52-Week LowLowest price in past year | $1.05 | $0.54 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +95.8% |
| RSI (14)Momentum oscillator 0–100 | 57.0 | 63.6 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 122K |
BFRI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BFRI leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). XTLB leads in 2 (Profitability & Efficiency, Total Returns).
Best OverallBiofrontera Inc. (BFRI)Leads 3 of 6 categories
Loading custom metrics...
XTLB vs BFRI: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — XTLB or BFRI?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -80. 4%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: XTLB returned -87. 3% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — XTLB or BFRI?
By beta (market sensitivity over 5 years), Biofrontera Inc.
(BFRI) is the lower-risk stock at 1. 67β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately 2% more volatile than BFRI relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 59% for Biofrontera Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — XTLB or BFRI?
Biofrontera Inc.
(BFRI) is the more profitable company, earning -25. 3% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BFRI leads at -27. 2% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — BFRI leads at 75. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — XTLB or BFRI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is XTLB or BFRI better for a retirement portfolio?
For long-horizon retirement investors, Biofrontera Inc.
(BFRI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BFRI: -98. 7%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between XTLB and BFRI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.